| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2135798 | Hematology/Oncology and Stem Cell Therapy | 2014 | 17 Pages |
Abstract
Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been linked to worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we update on the expression of B7-H1 molecule in solid and hematological malignancies. We also describe the possible mechanisms by which this molecule inhibits/downregulates the immune response to cancer cells. Finally, we highlight current and future potential therapeutic strategies that can be further developed to target this molecule.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sehar Afreen, Said Dermime,